NASDAQ$CTKB
Cytek Biosciences Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported solid year-over-year revenue growth despite industry headwinds.
Cytek Biosciences reported a 7% increase in revenue compared to the third quarter of 2023, driven by growth in EMEA and APAC regions and service revenue. The company reaffirms its 2024 revenue guidance.
- Total revenue for Q3 2024 was $51.5 million, a 7% increase year-over-year and a 10% increase over Q2 2024.
- Launched SpectroPanel™ tool, enhancing the Cytek® Cloud digital ecosystem.
- Expanded installed base to 2,821 Cytek instruments, adding 164 units in Q3 2024.
- Repurchased $12.1 million of Cytek common stock in Q3 2024.
Headline financials
Revenue & EPS history
Cytek Biosciences · Revenue · Quarterly
$51.5M
Revenue by segment
Cytek Biosciences · $48M total across 2 segments · Q3 2023
- Product Revenue$38.4M+5.6%80.1%
- Service Revenue$9.56M+133.8%19.9%
Forward guidance
Cytek Biosciences reaffirms its 2024 revenue guidance of full year 2024 revenue to be in the range of $203 million to $210 million, representing growth of 5% to 9% over full year 2023, assuming no change in currency exchange rates. In addition, Cytek continues to expect to report a net loss in the single digit millions for the full year 2024 and positive cash flow from operations in 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
-0.9%
Avg return
Earnings day
+0.6%
Avg return
5 days after
-4.5%
Avg return
30 days after
36%
8 / 22 earnings
Positive
+42.3%
Q3 2024
Best reaction
-23.6%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.6% | -18.4% | -17.2% | |
| Q4 2025 | +1.6% | +0.2% | -1.8% | |
| Q3 2025 | +2.6% | +21.5% | +27.6% | |
| Q1 2025 | -22.8% | -28.0% | -9.2% | |
| Q4 2024 | -6.7% | -7.1% | -16.8% | |
| Q3 2024 | +42.3% | +35.6% | +25.8% | |
| Q2 2024 | -12.7% | -10.5% | -6.7% | |
| Q1 2024 | -2.8% | -3.1% | -6.0% | |
| Q4 2023 | -13.0% | -8.2% | -12.9% | |
| Q3 2023 | +14.7% | +12.4% | +75.7% | |
| Q2 2023 | -2.0% | +2.4% | -25.1% | |
| Q1 2023 | -23.6% | -35.4% | -30.9% | |
| Q4 2022 | -10.0% | +0.7% | -15.5% | |
| Q3 2022 | -0.6% | +0.6% | -22.3% | |
| Q2 2022 | +1.0% | +1.9% | -4.0% | |
| Q1 2022 | +1.1% | +23.1% | +25.6% | |
| Q4 2021 | -1.9% | +1.3% | -26.5% | |
| Q3 2020 | +1.8% | -0.2% | -17.9% | |
| Q3 2021 | -0.9% | -4.4% | -19.0% | |
| Q2 2020 | -1.8% | +6.8% | -12.3% | |
| Q4 2020 | -1.8% | +6.8% | -12.3% | |
| Q2 2021 | +16.2% | +14.9% | +2.5% | |
| Q1 2021 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro